In this study, we found that Rosiglitazone treatment restored myocardin expression in Atp6v0d1AKO mice, suggesting that myocardin downregulation is a result of the systemic insulin resistance that occurs in diabetes, obesity and lipodystrophy. The gene discussed is MYOCD; the disease is obesity disorder.